Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details) $ in Millions		3 Months Ended
		Apr. 03, 2016 USD ($) Employee	Mar. 29, 2015 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated (in number of employees) | Employee		100
Restructuring charges	[1]	$ 30	$ 42
Worldwide Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		3	12
Manufacturing Operations [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		14	(22)
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		1	18
Global Innovative Pharmaceutical [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		8	12
Global Vaccines, Oncology and Consumer Healthcare [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		1	13
Global Established Pharmaceutical [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 3	$ 10

[1] In the three months ended April 3, 2016, Employee terminations represent the expected reduction of the workforce by approximately 100 employees, mainly in manufacturing. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges for the three months ended April 3, 2016 are associated with the following:•the Global Innovative Pharmaceutical segment (GIP) ($8 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($1 million); the Global Established Pharmaceutical segment (GEP) ($3 million); Worldwide Research and Development and Medical (WRD/M) ($3 million); manufacturing operations ($14 million); and Corporate ($1 million).The restructuring charges for the three months ended March 29, 2015 are associated with the following:•GIP ($12 million); VOC ($13 million); GEP ($10 million); WRD/M ($12 million); manufacturing operations ($22 million income); and Corporate ($18 million).